Render Target: STATIC
Render Timestamp: 2024-11-21T13:42:37.708Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-20 06:23:26.295
Product last modified at: 2024-10-09T12:45:14.077Z
1% for the planet logo
PDP - Template Name: Growth Factors and Cytokines
PDP - Template ID: *******9ad1159

Human IFN-α 2b Recombinant Protein #36000

    Product Information

    Storage

    Human IFN-α 2b Recombinant Protein is supplied as lyophilized material that is very stable at -20°C. It is recommended to reconstitute with sterile water at a concentration of 0.1 mg/mL which can be further diluted in aqueous solutions as needed. Addition of a carrier protein (0.1% HSA or BSA) is recommended for long-term storage.

    Once in solution, store at 4°C and use within 1 month, or store at -20ºC to -80ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles if storing reconstituted material at -20ºC to -80ºC.

    Product Description

    MW (kDa) 19.4
    Purity A greater than or equal to 95% purity was determined by SDS-PAGE.
    Endotoxin Endotoxin levels are less than or equal to 1 EU / 1 μg hIFN-α 2b.
    Activity The bioactivity of recombinant hIFN-α 2b was determined in a viral CPE assay using EMC virus on A549 cells. The ED50 of each lot is greater than or equal to 2.0 x 108 units/mg.

    Source / Purification

    Recombinant human IFN-α 2b was expressed in E. coli and is supplied in a lyophilized form.

    Background

    Interferons (IFNs) appear both locally and systematically early after viral infection and participate in limiting the spread of infection. They also affect cell differentiation, growth, surface antigen expression, and immunoregulation (1). There are three naturally occurring interferons: α, β, and γ. IFN-α is derived from lymphoblastic tissue and has a number of therapeutic applications in the treatment of various human cancers and diseases of viral origin. Recombinant IFN-α from both natural and synthetic genes binds to a common cell surface receptor and induces antiviral activity in a variety of cell lines. When binding to discrete cell surface receptors on target cells, IFN-α induces rapid changes in Jak/Stat phosphorylation, which initiates the Jak/Stat signaling pathway (2). IFN-α signaling also involves production of DAG without an increased intracellular free calcium concentration and the subsequent activation of calcium-independent isoforms of PKC (β and ε) (3). All IFN-α signaling pathways lead to final alterations of gene expression, which mediate their pleiotropic biologic activities.

    The human IFN-α 2 subvariants 2a and 2b differ by one or two amino acids at positions 23 and/or 34 of the mature protein (4). Pegylated forms of IFN-α 2 and recombinant IFN-α 2 protein are used clinically as standard treatments for anti-viral and anti-tumor therapies (5). IFN-α 2a and 2b proteins have also been shown to have implications in treating hepatitis C (6).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.